(en) D Yee, C Valiquette, M Pelletier, I Parisien, I Rocher et Dick Menzies, « Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis », American Journal of Respiratory and Critical Care Medicine, vol. 167, no 11, , p. 1472-1477. (PMID12569078, DOI10.1164/rccm.200206-626OC, lire en ligne)
(en) « Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. », MMWR Recommendations and Reports, vol. 49, no RR-6, , p. 1-51 (PMID10881762, lire en ligne)
(en) « Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis », The Lancet, vol. 1, no 8213, , p. 171-174 (PMID6109855, DOI10.1016/S0140-6736(02)95623-0, lire en ligne)
(en) East and Central African/British Medical Research Council Fifth Collaborative Study, « Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis », Tubercle, vol. 64, no 3, , p. 153-166 (PMID6356538, DOI10.1016/0041-3879(83)90011-9, lire en ligne)
(en) British Thoracic Society, « A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis Final report: Results during the 36 months after the end of chemotherapy and beyond », British Journal of Diseases of the Chest, vol. 78, , p. 330-336. (PMID6386028, DOI10.1016/0007-0971(84)90165-7, lire en ligne)
(en) D Yee, C Valiquette, M Pelletier, I Parisien, I Rocher et Dick Menzies, « Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis », American Journal of Respiratory and Critical Care Medicine, vol. 167, no 11, , p. 1472-1477. (PMID12569078, DOI10.1164/rccm.200206-626OC, lire en ligne)
(en) W Shi, X Zhang, X Jiang, H Yuan, JS Lee, CE Barry, H Wang, W Zhang et Y Zhang, « Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis: a potential mechanism for shortening the duration of tuberculosis chemotherapy », Science, vol. 333, no 6049, , p. 1630-1632 (PMID21835980, PMCID3502614, DOI10.1126/science.1208813)
(en) Y Zhang et D Mitchison, « The curious characteristics of pyrazinamide: a review », Int. J. Tuberc. Lung Dis., vol. 7, no 1, , p. 6-21 (PMID12701830, lire en ligne)
(en) « Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis », The Lancet, vol. 1, no 8213, , p. 171-174 (PMID6109855, DOI10.1016/S0140-6736(02)95623-0, lire en ligne)
(en) « Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. », MMWR Recommendations and Reports, vol. 49, no RR-6, , p. 1-51 (PMID10881762, lire en ligne)
(en) East and Central African/British Medical Research Council Fifth Collaborative Study, « Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis », Tubercle, vol. 64, no 3, , p. 153-166 (PMID6356538, DOI10.1016/0041-3879(83)90011-9, lire en ligne)
(en) British Thoracic Society, « A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis Final report: Results during the 36 months after the end of chemotherapy and beyond », British Journal of Diseases of the Chest, vol. 78, , p. 330-336. (PMID6386028, DOI10.1016/0007-0971(84)90165-7, lire en ligne)
(en) D Yee, C Valiquette, M Pelletier, I Parisien, I Rocher et Dick Menzies, « Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis », American Journal of Respiratory and Critical Care Medicine, vol. 167, no 11, , p. 1472-1477. (PMID12569078, DOI10.1164/rccm.200206-626OC, lire en ligne)
(en) Y Zhang et D Mitchison, « The curious characteristics of pyrazinamide: a review », Int. J. Tuberc. Lung Dis., vol. 7, no 1, , p. 6-21 (PMID12701830, lire en ligne)
(en) O Zimhony, JS Cox, JT Welch, C Vilchèze et WR Jacobs, « Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. », Nature Medecine, vol. 6, no 9, , p. 1043-1047 (PMID10973326)
(en) W Shi, X Zhang, X Jiang, H Yuan, JS Lee, CE Barry, H Wang, W Zhang et Y Zhang, « Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis: a potential mechanism for shortening the duration of tuberculosis chemotherapy », Science, vol. 333, no 6049, , p. 1630-1632 (PMID21835980, PMCID3502614, DOI10.1126/science.1208813)
(en) « Controlled trial of four thrice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis », The Lancet, vol. 1, no 8213, , p. 171-174 (PMID6109855, DOI10.1016/S0140-6736(02)95623-0, lire en ligne)
(en) East and Central African/British Medical Research Council Fifth Collaborative Study, « Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis », Tubercle, vol. 64, no 3, , p. 153-166 (PMID6356538, DOI10.1016/0041-3879(83)90011-9, lire en ligne)
(en) British Thoracic Society, « A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis Final report: Results during the 36 months after the end of chemotherapy and beyond », British Journal of Diseases of the Chest, vol. 78, , p. 330-336. (PMID6386028, DOI10.1016/0007-0971(84)90165-7, lire en ligne)
